Literature DB >> 6861596

Drug binding to plasma proteins during human pregnancy and in the perinatal period. Studies on cloxacillin and alprenolol.

L Herngren, M Ehrnebo, L O Boréus.   

Abstract

Plasma protein binding of one acidic drug, cloxacillin, and one basic drug, alprenolol, was determined by equilibrium dialysis at +37 degrees C during pregnancy and the 1st postnatal week in 12 women and their newborn infants and in 7 nonpregnant women (controls). A significant increase in fraction free cloxacillin in maternal plasma occurred during pregnancy already from the 2nd trimester compared to the controls (p less than 0.01) and was most pronounced at delivery (median values 0.126 and 0.069, respectively). A similarly increased fraction free cloxacillin was found in cord blood (median value 0.108) which further increased during the 1st postnatal week (range 0.112-0.164). In maternal plasma the binding capacity returned to the values of the controls during the same time period. The binding of cloxacillin was significantly correlated with the concentration of albumin (p less than 0.01). High correlation was also found between binding of the basic drug alprenolol and concentration of orosomucoid (p less than 0.005). This was most obvious in the newborn infants with low concentrations (range 0.1-0.3 g/l) and in the mothers during the puerperium with high concentrations of orosomucoid (range 0.7-2.5 g/l). On the basis of plasma protein binding data in the mother and her child, a maternal to fetal plasma concentration ratio was calculated. For cloxacillin this ratio was close to unity (1.03), while it was significantly above unity for alprenolol (1.72). At equilibrium, therefore, the total plasma concentration of alprenolol in the mother can be expected to exceed the concentration in her infant.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861596     DOI: 10.1159/000457284

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  19 in total

Review 1.  Plasma protein binding of drugs in pregnancy and in neonates.

Authors:  L J Notarianni
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 2.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

3.  Protein binding of the analgesics alfentanil and sufentanil in maternal and neonatal plasma.

Authors:  W Meuldermans; R Woestenborghs; H Noorduin; F Camu; A van Steenberge; J Heykants
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women.

Authors:  A Philipson; G Stiernstedt; M Ehrnebo
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

Review 5.  The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state.

Authors:  M D Hill; F P Abramson
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

6.  Cardiac arrhythmias during pregnancy.

Authors:  Thomas Adam Burkart; Jamie Beth Conti
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-10

7.  Longitudinal effects of pregnancy on the pharmacokinetics of theophylline.

Authors:  M J Gardner; M Schatz; L Cousins; R Zeiger; E Middleton; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 8.  Drug transfer and metabolism by the human placenta.

Authors:  Michael R Syme; James W Paxton; Jeffrey A Keelan
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 9.  The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation.

Authors:  G M Mitani; I Steinberg; E J Lien; E C Harrison; U Elkayam
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

10.  Differences in the binding of quinine and quinidine to plasma proteins.

Authors:  G W Mihaly; M S Ching; M B Klejn; J Paull; R A Smallwood
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.